Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gout
Biotech
Atom claims ph. 3 win shows gout drug can beat competition
Atom is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition.
James Waldron
Sep 8, 2025 9:01am
George Church spinout restructures, considers strategic options
Mar 13, 2025 2:00pm
GRO Bio gathers $60M series B to take gout therapy into clinic
Jul 19, 2024 9:59am
Selecta narrows focus to gout drug, freezing rest of pipeline
Aug 17, 2023 8:18am
Selecta, Sobi rout gout in phase 3 trials to take on Horizon
Mar 21, 2023 7:40am
Alnylam culls 3 programs, including once-touted nephropathy med
Dec 16, 2022 1:52pm
